We scan new podcasts and send you the top 5 insights daily.
In the CompassHER2 analysis, anatomical factors like nodal involvement and T stage did not predict pathologic complete response, with the lone exception of T3 tumors in ER-negative disease. Dr. Nadine Tung highlights that biological factors—such as receptor expression and genomic signatures—drive chemosensitivity much more than anatomical tumor volume, suggesting clinicians should base de-escalation decisions primarily on biological characteristics.
While ER-positive/HER2-positive breast cancer typically yields lower pCR rates (34% overall), the HER2-DX pCR score revealed an absolute 40% difference between low and high/medium scores. Patients with ER-positive tumors and high or medium scores achieved pCR rates of 58% to 61% with four cycles of THP, effectively identifying candidates who can safely forgo multi-agent chemotherapy despite traditionally lower response expectations.
Hormone receptor-positive (HR+) HER2+ breast cancers often show lower rates of pathologic complete response (pCR) to pre-surgical therapy. This is due to their slower-growing biology, not treatment ineffectiveness. Clinicians should recognize this nuance and not assume a worse prognosis based on pCR alone in this subtype.
For premenopausal patients with extensive nodal disease (e.g., N2), the clinical indication for chemotherapy is so strong that even a low-risk genomic score would not be enough to withhold treatment. This highlights the primacy of clinical staging over genomic data in certain high-risk scenarios.
While the HER2 pathway is the dominant driver for achieving an initial tumor response in HER2+/HR+ disease, targeting the ER pathway is critical for maintaining that response and achieving long-term benefit. This dual-targeting benefit becomes more apparent over extended periods, as seen in the Affinity trial.
For patients with 1-3 positive nodes and low-risk biology (e.g., low-grade lobular, low recurrence score), experts are comfortable deferring chemotherapy. This challenges traditional node-based risk assessment, prioritizing tumor biology to avoid unnecessary toxicity in otherwise high-risk patients.
Despite next-generation sequencing (NGS) identifying ERBB2 amplification, clinicians still order immunohistochemistry (IHC) tests. The IHC score (e.g., 3+) provides a quantitative measure of protein expression, which can offer greater confidence in the efficacy of HER2-targeted therapies and help decide between treatment options.
Dr. O'Shaughnessy immediately adopted the Prosigna ROR score from the OPTIMA trial to guide chemotherapy decisions, even in patients with 4-9 positive lymph nodes, trusting tumor biology over high-risk anatomical features.
Clinicians are pushing back against simple "negative" HER2 pathology reports, demanding detailed Immunohistochemistry (IHC) scores (0, 1+, 2+, 3+) and the criteria used. This granular data is crucial for determining eligibility for modern treatments like antibody-drug conjugates (ADCs), where even low protein expression can be clinically relevant and actionable for patient care.
HER2+/ER+ breast cancer is not a single disease. Genomic subtyping reveals distinct biological profiles (luminal A/B, HER2-enriched) with pathologic complete response rates to therapy ranging from just 26% to as high as 61%, signaling the need for tailored treatment strategies.
A key debate in early HER2+ breast cancer is whether to use TDXD neoadjuvantly (DESTINY-Breast11) or reserve it for post-op residual disease (DESTINY-Breast05). Many experts favor the neoadjuvant approach to maximize the chance of a pathologic complete response (pCR), which allows for surgical de-escalation and is associated with better outcomes.